DakeMD. 12-month results from the Venovo venous stent trial. In: Vascular interventional advances conference. Las Vegas, NV, USA, 5–8 November 2018.
4.
DakeM. Treatment of venous iliofemoral occlusive disease with a self-expanding venous stent: a “first look” at 24-month results from the prospective, multicenter VERNACULAR trial. In: CIRSE, Barcelona, Spain, 8 September 2019.
5.
LundhALexchinJMintzesB, et al.
Industry sponsorship and research outcome. Cochrane Database Syst Rev2017;
2: MR000033.
6.
PowellJTSweetingMJUlugP, et al.; EVAR-1, DREAM, OVER and ACE Trialists.
Meta-analysis of individual-patient data from EVAR-1, DREAM, over and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg2017;
104: 166–178.
7.
GrayWAKeirseKSogaY, et al.
A polymer-coated, paclitaxel-eluting stent (eluvia) versus a polymer-free, paclitaxel-coated stent (zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet2018;
392: 1541–1551.
8.
van VuurenTMvan LaanenJHHde GeusM, et al.
A randomized controlled trial comparing venous stenting with conservative treatment in patients with deep venous obstruction: research protocol. BMJ Open2017;
7: e017233.
9.
JalaieHSchleimerKBarbatiME, et al.
Interventional treatment of postthrombotic syndrome. Gefasschirurgie2016;
21: 37–44.
10.
CatarinellaFSNiemanFHWittensCH.An overview of the most commonly used venous quality of life and clinical outcome measurements. J Vasc Surg Venous Lymphat Disord2015;
3: 333–340. Jul
11.
CatarinellaFSNiemanFHWittensCH.The relation between clinical scores and quality-of-life in long-term follow-up. Phlebology2016;
31: 99–105.
PorterMETeisbergEO.Redefining healthcare.
Boston:
Harvard Business School Press, 2006.
14.
NanoJCarinciFOkunadeO, et al. A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach. Diabet Med2020. Epub ahead of print.
15.
EklöfBRutherfordRBBerganJJ, et al.
Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg1995;
21: 1248–1252.
16.
VillaltaSBagatellaPPiccioliA, et al.
Assessment of validity and reproducibility of a clinical scale for the postthrombotic syndrome. Haemostasis1994;
24: 158a.
17.
VasquezMAMunschauerCE.Revised venous clinical severity score: a facile measurement of outcomes in venous disease. Phlebology2012;
27: 119–129.
18.
StrijkersRHArnoldussenCWWittensCH.Validation of the LET classification. Phlebology2015;
30: 14–19.
19.
ArnoldussenCWKPToonderIWittensCHA.A novel scoring system for lower-extremity venous pathology analysed using magnetic resonance venography and duplex ultrasound. Phlebology2012;
27(Suppl 1): 163–170.
20.
StewartALHaysRDWareJEJr.The MOS short-form general health survey: reliability and validity in a patient population. Med Care1988;
26: 724–735. 22.
SmithJJGarrattAMGuestM, et al.
Evaluating and improving health-related quality of life in patients with varicose veins. J Vasc Surg1999;
30: 710–719.
23.
LaunoisRLe MoineJGLozanoFS, et al.
Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure. Qual Life Res2012;
21: 1051–1058.
24.
AbenhaimLKurzX.The VEINES study (VEnous INsufficiency epidemiologic and economic study): an international cohort study on chronic venous disorders of the leg. Angiology1997;
48: 59–66.
